MorphoSys acquires Biogenesis in UK and US
German-based MorphoSys has acquired two privately held companies, Biogenesis Ltd, of Poole in the UK, and its sister company Biogenesis Inc., of Brentwood, New Hampshire, US.
German-based MorphoSys has acquired two privately held companies, Biogenesis Ltd, of Poole in the UK, and its sister company Biogenesis Inc., of Brentwood, New Hampshire, US.
With more than 20 years' experience in antibody development and manufacturing, and a comprehensive antibody catalogue, the combined Biogenesis group represents one of the larger European suppliers of antibodies to the life sciences research community.
The two Biogenesis companies will become wholly owned subsidiaries of MorphoSys. John Coward, managing director of Biogenesis Ltd., will become chairman of the UK subsidiary and Joan Poehlman, president of Biogenesis Inc., will serve as president of the US subsidiary. The acquisition will establish MorphoSys as one of the top five European suppliers.
'The transaction will help MorphoSys build the market for its HuCAL technology by strengthening our position outside our core therapeutic antibody segment,' said Dr Simon Moroney, ceo MorphoSys. 'It will also provide the company with access to well-established sales channels and substantial know-how in the research and diagnostics markets.'